Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
Two months after Centessa Pharmaceuticals launched following the merger of 10 private biotech companies, the company is already eying a $100 million splash on the Nasdaq stock exchange.
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
The medical device maker has been dropping money like rain this spring, spending close to $19 billion in acquisitions over the past four months.
Recursion Pharma is getting bigger and bigger with its new public offering. The Recursion Pharmaceuticals IPO is anticipated to bring approx $306 million.
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
April springs up with showers of cash for these life sciences companies.